FDA approves amendments to Oxford BioMedica TroVax study
Oxford BioMedica plc said today, October 7, that the US Food and Drug Administration (FDA) had approved a series of amendments to the PHASE III TRIST study of its lead drug TroVax in renal cancer.
Roche gets UK approval for low-cost Tarceva
The National Institute for Health and Clinical Excellence has recommended Roche’s Tarceva for use on the National Health Service after the Swiss drugmaker agreed to cut the price of the lung cancer drug.
United Drug FY 2008 earnings to meet forecasts
United Drug plc said it will meet its targets of a double-digit increase in operating profit and earnings for the year ending September 30.
Zentiva board agrees Sanofi offer
Zentiva NV have said its board unanimously recommended that shareholders accept an all-cash bid of CZK1,150 per share by French drugmaker Sanofi-Aventis SA.
GSK may shed 6% of R&D jobs
GlaxoSmithKline plc is planning to cut up to 850 research and development jobs in Britain and the United States, in a bid to improve productivity.
Claimar not expecting to meet forecasts
In a trading update today, September 29, care services provider Claimar Care Group plc said it sees normalised full-year pretax profit at the lower end of market expectations.